newsfilter
← Latest News
GlobeNewswire·

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer's Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam.